

Michael Pfaller

List of Publications by Citations

Source: <https://exaly.com/author-pdf/9336718/michael-pfaller-publications-by-citations.pdf>
Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

14 papers	2,371 citations	11 h-index	15 g-index
15 ext. papers	2,642 ext. citations	4.8 avg, IF	4.22 L-index

#	Paper	IF	Citations
14	Attributable mortality of nosocomial candidemia, revisited. <i>Clinical Infectious Diseases</i> , 2003 , 37, 1172-7	11.6	879
13	Risk factors for candidemia in Neonatal Intensive Care Unit patients. The National Epidemiology of Mycosis Survey study group. <i>Pediatric Infectious Disease Journal</i> , 2000 , 19, 319-24	3.4	480
12	Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance [®]) registry, 2004-2008. <i>Diagnostic Microbiology and Infectious Disease</i> , 2012 , 74, 323-31	2.9	271
11	The changing epidemiology of healthcare-associated candidemia over three decades. <i>Diagnostic Microbiology and Infectious Disease</i> , 2012 , 73, 45-8	2.9	234
10	The PATH (Prospective Antifungal Therapy) Alliance [®] registry and invasive fungal infections: update 2012. <i>Diagnostic Microbiology and Infectious Disease</i> , 2012 , 73, 293-300	2.9	173
9	Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility. <i>Antimicrobial Agents and Chemotherapy</i> , 2006 , 50, 2892-4	5.9	156
8	Decreased susceptibility of Candida albicans to azole antifungals: a complication of long-term treatment in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2007 , 60, 889-92	5.1	42
7	Candidemia surveillance in Iowa: emergence of echinocandin resistance. <i>Diagnostic Microbiology and Infectious Disease</i> , 2014 , 79, 205-8	2.9	38
6	Optimizing Echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against Candida glabrata with and without fks mutations. <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 5875-82	5.9	36
5	Reduction of fluconazole susceptibility of Candida albicans in APECED patients due to long-term use of ketoconazole and miconazole. <i>Scandinavian Journal of Infectious Diseases</i> , 2008 , 40, 904-7		32
4	Evaluation of CLSI M44-A2 disk diffusion and associated breakpoint testing of caspofungin and micafungin using a well-characterized panel of wild-type and fks hot spot mutant Candida isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2011 , 55, 1891-5	5.9	17
3	Application of Culture-Independent Rapid Diagnostic Tests in the Management of Invasive Candidiasis and Cryptococcosis. <i>Journal of Fungi (Basel, Switzerland)</i> , 2015 , 1, 217-251	5.6	7
2	Emerging Resistance to Azoles and Echinocandins: Clinical Relevance and Laboratory Detection. <i>Current Fungal Infection Reports</i> , 2010 , 4, 186-195	1.4	5
1	Evaluation of Rezafungin Provisional CLSI Clinical Breakpoints and Epidemiological Cutoff Values Tested against a Worldwide Collection of Contemporaneous Invasive Fungal Isolates (2019 to 2020).. <i>Journal of Clinical Microbiology</i> , 2022 , e0244921	9.7	0